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Abstract
Background: Primary orbital lymphoma is a rare disease that accounts for 10% of all orbital
tumors. Radiotherapy on the orbital cavity is the treatment of choice for this unusual presentation
of localized non-Hodgkin's lymphoma (NHL). The aim of this study is to retrospectively evaluate
the effectiveness and the toxicity of radiation treatment in patients with primary orbital lymphoma.
Methods: Forty-seven consecutive patients having primary orbital lymphoma treated in our
department between May 1983 and September 2006 were investigated in a retrospective study.
Either 60Co γ rays or 6 MV X rays were used to deliver daily fractions of 1.8 or 2.0 Gy, 5 times/
week, with total doses ranging from 34.2 to 50 Gy. Forty-three patients had stage IE, three had
stage II and one stage IV disease. Thirty-eight patients had marginal zone B-cell lymphoma, 5 diffuse
large B cell lymphoma, 3 mantle cell lymphoma and 1 Burkitt lymphoma. Local control (LC), disease
free survival (DFS), overall survival (OS) and late side effects were evaluated in all patients.
Results: With a median follow up of 45 months, LC was obtained in 100% of patients. The
estimated 5- and 7-year DFS rates were 75.8% and 55.3%, and the 5- and 7-year OS rates were
88.7% and 79.9% respectively. Acute toxicity was minimal. Late toxicity such as cataract, keratitis,
retinopathy and xerophthalmia occurred respectively in 12 (25.5%), 5 (10.6%), 1 (2.1%), and 9
(19.1%) patients.
Conclusion: Radiotherapy is an effective and at the same time well tolerated treatment for
primary orbital lymphoma.
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The orbit is a rare site of presentation of non-Hodgkin's
lymphoma (NHL). Primary orbit lymphoma (POL) repre-
sents 1% of all NHLs and 8% of extranodal NHLs [1].
Bilateral involvement occurs in 10-15% of cases of POL
[2]. The majority of patients at the time of diagnosis are
over 65 [3,4]. The commonest manifestation of the dis-
ease is a slowly growing orbital mass that can be either
asymptomatic, or, depending on the location of the
tumor, associated with proptosis, ocular dysmotility, peri-
orbital swelling, blurring of vision and chemosis. The
most frequent histology of POL is indolent NHL such as
extranodal marginal B-cell lymphoma of mucosa-associ-
ated lymphoid tissue (MALT) [5-8]. Usually therapeutic
management of POL consists of radiation treatment [6,8-
25] encompassing the entire orbit [26]. At present it is
known that radiotherapy, using low or moderate doses in
the range of 25-36 Gy, can obtain 95-100% of local con-
trol. However, due to the rarity of the disease, data about
doses from comparative studies are not available and,
moreover, in reports with a substantial number of treated
patients, doses in the range of 20 and 57 Gy were found
to be used [6,8-25]. For patients with advanced disease,
sequential chemo-radiation treatment is preferred [8].
In this study we have retrospectively evaluated the effec-
tiveness and late toxicity of radiation therapy in 47 con-
secutive patients with a diagnosis of POL treated at the
Radiation Oncology Department of the Medical School of
the University "Federico II" of Naples. In particular, we
evaluated our treatment with respect to local control (LC),
disease free survival (DFS), overall survival (OS), and inci-
dence of late side effects such as cataract, keratitis and
xerophthalmia.
Methods
Patient section
From May 1983 to September 2006, 47 patients (and 49
orbits) affected with primary biopsy-proven orbital NHL
were treated at the Radiotherapy Department of Univer-
sity "Federico II" of Naples. Patient's median age at diag-
nosis was 62 years (range 33-88 years). The vast majority
(38 out of 47) of patients had extranodal marginal zone
B-cell lymphoma of mucosa-associated limphoid tissue
(MALT) type NHL according to REAL classification [27].
All patients had medical history and physical examination
and underwent orbits CT scan and bone marrow biopsy.
Thirty four (72.3%) patients underwent further staging by
total body CT scan, 11 (23.4%) by total body 18FDG-PET
scan, and 2 (4.3%) by chest X-ray. Forty three out of 47
patients resulted to have stage IE, 3 patients had stage II (2
bilateral orbital involvement and 1 ipsilateral parotid
involvement) and 1 stage IV disease (bone marrow
involvement) according to Ann-Arbor classification.
Detailed description of patient features is reported in table
1.
Treatment
Radiation treatment was delivered with total doses rang-
ing from 34.2 to 50 Gy with a median dose of 36 Gy
administered by daily fractions of 1.8-2.0 Gy, 5 times/
week. From 1981 to 1998, the treatment was adminis-
tered by Co-60-gamma-Ray (14 patients), and since 1999
the treatment was administered with 6 MV X photons
from a LINAC (33 patients). For 43 patients, a direct ante-
rior field was used, while an anterior plus a lateral field
was used for the remaining 4 patients. The whole orbital
cavity was included in the target. For the patient with
parotid involvement, we used a separate additional elec-
tron beam lateral field encompassing the whole gland. In
all patients treated by LINAC, a CT based simulation soft-
ware (Computerized Medical System, Inc., St Louis, MO)
for target and lens contouring was used and treatment
planning was performed by a 3-D planning system (XiO
4.4, Computerized Medical System, Inc., St Louis, MO).
Lens shielding was performed for the treatment of 38
(77.6%) orbits in which tumour coverage was not com-
promised and the site of disease was not eyelid or con-
junctiva. For the anterior field, lens shielding was
obtained using eye customized shielding block placed on
the blocking tray over the lens, and checked daily by the
physician. When the lateral field was used, the anterior
border was always placed posterior to the lens. Superficial
Table 1: Patients' clinical features.
Patients N. %
Gender
Male 20 42.6
Female 27 57.4
Localization*
Orbital cavity 41 83.7
Lachrymal sac 1 2.0
Conjunctiva 3 6.1
Eyelid 4 8.2
Histology
B cell MALT lymphoma 38 80.9
Diffuse large B cell lymphoma 5 10.6
Mantle cell lymphoma 3 6.4
Burkitt lymphoma 1 2.1
Stage
I 43 91.5
II 3 6.4
III 0 0
IV 1 2.1
* Total number of localizations are 49 since two patients had bilateral 
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treated without lens shielding and with bolus to bring the
isodose curve to surface for adequate coverage. Details on
prescribed radiation doses are reported in table 2.
Two patients received systemic chemotherapy: one
patient, with aggressive Burkitt Stage I orbital lymphoma,
underwent concomitant chemo-radiation therapy; the
other one, with Stage IV disease, had first chemotherapy,
then radiotherapy on the residual orbital mass.
Acute and late ocular side effects were evaluated and
graded according to RTOG toxicity score.
The follow-up consisted in patient's history, physical
examination, ophthalmologist evaluation every 4 months
and an imaging study of the orbits that included either CT
or MRI or ultrasonography scan. Total body CT scan was
prescribed yearly for 5 years.
Statistical Analysis
Categorical data were expressed as percentage. Chi-square
analysis with Yates correction and Fisher's exact test were
applied when appropriate; a p-value of 0.05 was chosen as
significant.
Local Control (LC), disease free survival (DFS) and overall
survival (OS) were analyzed statistically in all patients.
DFS was calculated from the date of the end of the radia-
tion therapy to the date of first documented relapse
(event). A patient dead for any other cause or a patient lost
to follow-up for reasons unrelated to the study was con-
sidered a censored observation. OS was calculated from
the date of the end of the radiation therapy to the date of
death or the date of the last follow up. The Kaplan-Meier
method was used to estimate the rates of DFS and OS. Sta-
tistical evaluation was carried out using SPSS 13.0 statisti-
cal software.
Results
At the first control after radiotherapy, all patients resulted
free of disease. With a median follow up of 45 months
(range 5-203) no local relapses were observed and the LC
resulted to be 100%.
Twelve (25.5%) patients failed distantly with a median
time for failure of 44 months: two patients relapsed in the
other eye, 4 at ipsilateral laterocervical nodes, 3 in the
abdomen, 1 in the mediastinum, 1 in the trunk skin, and
1 in a vertebral bone. All relapsed patients but one had
undergone total body CT scan at the time of diagnosis.
Eight out of 43 (18.6%) Stage I patients failed distantly,
while 4 out of 4 (100%) Stage II-IV patients failed dis-
tantly (p = 0.003). Eight out of 38 patients with MALT
type lymphoma failed distantly and 4 out of 9 patients
with different histotype failed distantly (p = 0.15).
The 5- and 7-year DFS rates were 75.8% and 55.3% (Fig-
ure. 1), respectively and the 5- and 7-year OS rates were
88.7%and 79.9% (Figure. 2).
All the relapsed patients underwent second line therapy
(radio or chemotherapy). Nine are presently free of dis-
ease, 2 are alive with disease, and 1 is death for lymphoma
(Cause Specific Survival was 97.9%). Four patients (8.5%)
died from non lymphoma-related causes.
None of the patients developed significant acute toxicity;
the most frequent side effects were mild conjunctivitis,
excessive tearing or dryness, and periorbital erythema or
Table 2: Radiation doses. Fraction dose 1.8 - 2.0 Gy.
Total dose (Gy) Patient N. (%)
34.2 1 (2.1)
36 28 (59.6)
40 6 (12.8)
41.4 1 (2.1)
42 1 (2.1)
44 5 (10.6)
45 1 (2.1)
46 1 (2.1)
50 3 (6.4)
Disease-Free Survival (DFS)Figure 1
Disease-Free Survival (DFS). The delay of DFS was calcu-
lated from the date of the end of radiotherapy until the date 
of revealing of a progress or until the date of death, or until 
the date of last news (47 patients, 12 events, 35 censored).Page 3 of 6
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three (48.9%) patients had G1 toxicity and only 2 (4.3%)
had G2 toxicity and required artificial tears during radia-
tion treatment.
As a whole, no G3-4 RTOG late side effects were reported
in any patient. Keratitis occurred in 5 patients (10.6%),
xerophthalmia in 9 (19.1%), cataract in 12 (25.5%), cor-
neal ulceration occurred in one patient (2.1%), and minor
retinopathy in one (2.1%).
Cataract, minor retinopathy and corneal ulceration
occurred in 20.7% patients among those treated with a
dose ≤ 36 Gy (6 on 29 patients), and in 44.4% patients
among those treated with doses > 36 Gy (8 on 18
patients) (p = 0.083).
A lens-sparing technique was used in all patients with the
exception of 9 patients for which lens shielding was not
used because tumour coverage could be compromised.
Three of 9 patients (33%) without lens shielding devel-
oped cataract, while 9 of 38 patients (23%) with lens
shielding developed cataract (p = 0.31).
Discussion
In POL bearing patients, a complete staging evaluation is
necessary at first diagnosis for treatment decision [10,18].
Exclusive surgical approach is not recommended because
of the high rate of local relapses [23], probably as a result
of the inherent difficulty of preserving ocular function and
encompassing all local disease; so surgery is limited to
biopsy. Esik et al., comparing different modalities of treat-
ment for orbital NHL, showed a 10-year local control of
0% in the group of patients treated with surgery only.
Although observation [28] or first line chemotherapy
[29,30] have been recently proposed and sequential
chemo-radiotherapy is more judicious for treating inter-
mediate/high grade lymphomas [11] and primary sys-
temic disease [8], at present radiotherapy is the treatment
of choice for NHL localized in the orbital cavity. Accord-
ing to literature [6,8-25], it is possible to obtain local con-
trol in the range of 89-100% using radiotherapy in low or
moderate doses as 25-36 Gy. A summary of findings of
some of published major studies on the issue is shown in
table 3.
Recently, in a review of the literature on radiation treat-
ment of POL, Yadav et al. report about acute and late tox-
icity of this type of therapeutic modality. The most
frequent acute side effect is conjunctivitis that should be
treated with artificial tears, while the most frequent late
toxicity is cataract that is today treated in a safe and effi-
cient way by surgical technique [31].
In our series, a median treatment dose of 36 Gy was used
to treat patients affected with POL. At a median follow-up
of 45 months local control rate of 100% was obtained.
Eight out of 43 (18.6%) Stage I patients failed distantly,
while 4 out of 4 (100%) Stage II-IV patients failed dis-
tantly. Disease stage at diagnosis influenced the systemic
relapse incidence (p = 0.003), while histologic grade did
not significantly influence outcome, maybe also due to
the low number of patients compared. Some studies sug-
gested a dose of 36-40 Gy for high-grade orbital NHL
[11,23]. In our series, radiation doses for non MALT type
NHL were slightly greater than doses used for MALT type
disease, with a median of 40 Gy. However, given the excel-
lent local control, no dose relation was found at the out-
come.
Prognostic value of age has been reported in POL, show-
ing that patients older than 64 year fared worse than
younger patients [18]. In the present study we have strati-
fied patients according to the age into two groups, one of
patients older than 64 year and the other group including
the younger patients. However, no differences in DFS (p =
0.73) were found.
Considering late side effects, cataract, minor retinopathy
and corneal ulceration developed in 30% of patients (14
out of 47). As expected, toxicity was more frequent in
patients receiving more than 36 Gy, although the differ-
ence did not reach statistical significance (p = 0.083),
probably due to the low number of events. Nevertheless,
Overall survival (OS)Figure 2
Overall survival (OS). The delay of OS was calculated 
from the date of the end of radiotherapy until the patient's 
death or until the date of last news (47 patients, 4 events, 43 
censored).Page 4 of 6
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cataract development like diabetes mellitus, drugs, famil-
iar predisposition and age cannot be excluded. As a whole,
the incidence and the severity of acute and late toxicity
were acceptable and consistent with other reports [18,31].
Our data, according to literature, support radiation ther-
apy as principal treatment modality in orbital localization
of NHL and suggest that the optimal dose to achieve both
disease control and minimum late effects has not to be
greater than 36 Gy. At present the dose used in our depart-
ment is 30 Gy as recommended by current literature.
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